Single-molecule DNA sequencing of acute myeloid leukemia and myelodysplastic syndromes with multiple TP53 alterations

Haematologica

Volumn 103, Issue 1, 2018, Pages E13-E16

  Lodé, Laurence ^a,b   Ameur, Adam ^c   Coste, Thibault ^a,e   Ménard, Audrey ^b   Richebourg, Steven ^b,d   Gaillard, Jean Baptiste ^e   Le Bris, Yannick ^b   Béné, Marie Christine ^b   Lavabre Bertrand, Thierry ^e   Soussi, Thierry ^f,g,h  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c UPPSALA UNIVERSITY   (Sweden)

^d LAVAL UNIVERSITY   (Canada)

^e Nimes University Hospital   (France)

^f SORBONNE UNIVERSITÉ   (France)

^g CENTRE DE RECHERCHE DES CORDELIERS   (France)

^h KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; TP53 PROTEIN, HUMAN;

ACUTE MYELOID LEUKEMIA; CANCER PATIENT; CHRONIC LYMPHATIC LEUKEMIA; DNA SEQUENCE; GENE FREQUENCY; GENE MUTATION; GENETIC BACKGROUND; HAPLOTYPE; HUMAN; LETTER; MULTIPLE TP53 MUTATION; MYELODYSPLASTIC SYNDROME; RNA SEQUENCE; SANGER SEQUENCING; STEM CELL TRANSPLANTATION; TUMOR GROWTH; ALLELE; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETIC VARIATION; GENETICS; HIGH THROUGHPUT SEQUENCING; MORTALITY; MUTATION; PATHOLOGY; PROGNOSIS;

ALLELES; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LEUKEMIA, MYELOID, ACUTE; MUTATION; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; SEQUENCE ANALYSIS, DNA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 85040066315     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2017.176719     Document Type: Letter

References (12)

1. Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016; 374(23):2209-2221.
2. Jadersten M, Saft L, Smith A, et al. TP53 Mutations in low-risk myelodysplastic syndromes with del(5q) predict disease Progression. J Clin Oncol. 2011;29(15):1971-1979.
3. Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-447.
4. Malcovati L, Hellström-Lindberg E, Bowen D, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013; 122(17):2943-2964.
5. Stengel A, Kern W, Haferlach T, Meggendorfer M, Fasan A, Haferlach C. The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases. Leukemia. 2017;31(3):705-711.
6. Mossner M, Jann JC, Nowak D, et al. Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS). Leukemia. 2016;30(9):1956-1959.
7. da Silva-Coelho P, Kroeze LI, Yoshida K, et al. Clonal evolution in myelodysplastic syndromes. Nat Commun. 2017; 815099.
8. Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: A looking glass for cancer? Nat Rev Cancer. 2012;12(5):323-334.
9. Leroy B, Ballinger ML, Baran-Marszak F, et al. Recommended guidelines for validation, quality control, and reporting of TP53 variants in clinical practice. Cancer Res. 2017;77(6):1250-1260.
10. Leroy B, Anderson M, Soussi T. TP53 mutations in human cancer: database reassessment and prospects for the next decade. Hum Mutat. 2014;35(6):672-688.
11. Lindsley RC, Saber W, Mar BG, et al. Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation. N Engl J Med. 2017;376(6):536-547.
12. Anensen N, Hjelle SM, Van Belle W, et al. Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia. Oncogene. 2012;31(12):1533-1545.